Information Provided By: 
Fly News Breaks for June 17, 2019
TEVA
Jun 17, 2019 | 07:08 EDT
Citi analyst Liav Abraham cut her price target for Teva Pharmaceutical to $13 from $23 after exploring some of the key questions and issues associated with the company's opioid litigation. The analyst, who keeps a Buy rating on the shares, acknowledges that the "highly complex nature of the litigation implies that certain questions remain unanswered."
News For TEVA From the Last 2 Days
There are no results for your query TEVA
